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Abstract
Pancreatic cancer (PC) remains one of the most aggressive tumors with an increasing incidence rate and reduced survival. 
Although surgical resection is the only potentially curative treatment for PC, only 15–20% of patients are resectable at diag-
nosis. To select the most appropriate treatment and thus improve outcomes, the diagnostic and therapeutic strategy for each 
patient with PC should be discussed within a multidisciplinary expert team. Clinical decision-making should be evidence-
based, considering the staging of the tumor, the performance status and preferences of the patient. The aim of this guideline 
is to provide practical and evidence-based recommendations for the management of PC.
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Introduction
Pancreatic cancer (PC) represents the fourth leading cause of 
cancer-related death, and it has been estimated to become the 
second by 2030 [1, 2]. PC is divided into four general cat-
egories: resectable, borderline resectable, locally advanced/
unresectable, and metastatic. Surgical resection remains the 
primary curative treatment for patients with PC, although 
only 15–20% will present with initially resectable disease. 
Approximately 30–40% of patients show locally advanced 
PC, and another 40% have distant metastatic disease [3–5].
Over the past decades, there has been considerable 
improvement in imaging and surgical techniques, and more 
effective chemotherapy and radiotherapy techniques have 
been developed [6, 7]. Decisions about the appropriate 
diagnostic and therapeutic strategy for each patient with 
PC should involve a multidisciplinary team involving radi-
ologists, gastroenterologists, surgeons, medical oncologists, 
radiation oncologists, endocrinologists, and pathologists 
with expertise in the management of pancreatic cancer [8]. 
The aim of this guideline is to summarize the current evi-
dence and to give practical and evidence-based recommen-
dations for the diagnosis and treatment of PC.
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Methodology
A group of seven experts—one from each Society- from the 
Spanish Society of Medical Oncology (SEOM), the Span-
ish Association of Surgeons (AEC), the Spanish Society of 
Radiation Oncology (SEOR), the Spanish Society of Endo-
crinology (SEEN), the Spanish Society of Digestive Pathol-
ogy (SEPD), the Spanish Society of Medical Radiology 
(SERAM), and the Spanish Society of Pathology (SEAP) 
met to discuss and provide a multidisciplinary consensus 
on the management of pancreatic cancer. In this consen-
sus, we provide 40 clinical questions addressing diagnosis, 
chemotherapy, radiation therapy, surgical treatments, and 
supportive therapy. The available medical literature was 
reviewed, and answers are given to each clinical question 
classified by scientific levels of evidence and the strength of 
recommendation [9].
Diagnosis and staging
What is the best imaging modality for the diagnosis 
and staging of PC?
Multidetector computed tomography (MDCT) with angi-
ography (at the pancreatic arterial [40–50 s] and portal 
venous [65–70 s] phases) is currently the worldwide imaging 
modality of choice for the evaluation of PC. MDCT provides 
three-dimensional (3D) multiplanar reconstruction images 
that enable the determination of tumor size, extent (vascular 
involvement), and spread [3, 10, 11] (quality of evidence: A; 
strength of recommendation: strong).
Magnetic resonance imaging (MRI) may be helpful 
for differentiating an inflammatory pancreatic mass from 
pancreatic adenocarcinoma, detecting isoattenuating PC, 
characterizing small tumors (< 1 cm) or hepatic lesions, or 
detecting metastases to the liver [12, 13].
What are the indications for endoscopic 
ultrasonography (EUS)?
EUS is indicated to diagnose PC in cases of inconclusive 
MDCT findings, to obtain cytohistological samples for path-
ological confirmation, and—complementary to MDCT—
for loco-regional staging [13–16] (quality of evidence: B; 
strength of recommendation: moderate).
EUS is particularly useful for the detection of small pan-
creatic lesions that cannot be identified by other imaging 
techniques [14]. EUS-guided biopsy is preferred over per-
cutaneous puncture because of its higher diagnostic yield 
(> 90%), safety and lower risk of seeding [15]. A recent 
meta-analysis showed that EUS had a sensitivity and speci-
ficity of 72% and 90% for T1–T2 staging and 90% and 70% 
for T3–T4 staging, respectively [16].
When is cytohistological confirmation necessary 
before starting treatment?
A pathologic diagnosis is indicated before administra-
tion of neoadjuvant therapy in patients with borderline or 
unresectable lesions, in the presence of metastatic disease 
or in patients with atypical presentation where a differen-
tial diagnosis with other pancreatic masses (autoimmune 
pancreatitis, lymphoma, chronic pancreatitis, tuberculosis, 
metastases) is needed. If a biopsy does not confirm malig-
nancy, it should be repeated at least once. A positive biopsy 
is not required in patients with clinically and radiologically 
suspected resectable PC before surgical resection because 
it may result in seeding, interfere with definitive surgery, 
and delay surgical resection if nondiagnostic [8, 15, 17, 
18] (quality of evidence: B; strength of recommendation: 
strong).
When is biliary drainage indicated before surgery, 
and how is it performed?
Early surgery without previous drainage remains the treat-
ment of choice in patients with resectable PC. Preoperative 
biliary drainage is mainly indicated in patients with chol-
angitis and in those with obstructive jaundice scheduled 
for neoadjuvant therapy [19–21]. Endoscopic retrograde 
placement of a fully covered metal stent is preferred over 
plastic stents or percutaneous drainage due to a lower com-
plication rate [20, 22]. Endoscopic ultrasound-guided stent 
placement is an effective and safe alternative [23] (quality of 
evidence: A; strength of recommendation: strong).
How is resectability/unresectability of PC defined?
Current criteria for resectability include the absence of dis-
tant metastases, no evidence of tumor involvement of major 
arteries, and, if there is venous invasion, a suitable seg-
ment of the superior mesenteric vein below and portal vein 
above the site of venous involvement to allow for venous 
reconstruction [8, 10, 12, 24, 25] (Table 1) (quality of evi-
dence: B; strength of recommendation: strong).
Surgical treatment
When is surgical treatment indicated for PC?
The selection of patients for surgery should be based not 
only on anatomic criteria (relationship between the tumor 
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and vessels) but also on biological (duration of symptoms 
and a CA 19–9 level suggestive of localized disease in the 
absence of jaundice) and conditional factors (a comorbidity 
profile appropriate for a major abdominal operation and an 
Eastern Cooperative Oncology Group (ECOG) performance 
status of 2 or more) [4, 5, 8, 17] (quality of evidence: B; 
strength of recommendation: strong).
What operative technique should be used 
for patients with PC according to the localization?
The only curative treatment for PC is radical surgery. The 
aim of surgery is to obtain microscopically negative margins 
(R0). Pancreaticoduodenectomy (Whipple procedure) is the 
procedure of choice for patients with tumors located in the 
head of the pancreas and the uncinated process. Patients with 
tumors of the body or tail of the pancreas are treated with 
distal pancreatectomy with splenectomy [26] (quality of evi-
dence: A; strength of recommendation: strong).
Although laparoscopic and robotic pancreatectomy is a 
feasible alternative to open surgery, the evidence regarding 
clinical and oncologic outcomes is limited [27]. A recent 
open-label, single-center, randomized controlled trial com-
pared the perioperative outcomes of 66 patients who under-
went pancreatoduodenectomy to treat benign, premalignant 
or malignant conditions, that was performed using a lapa-
roscopic approach or by open-surgery [28]. Patients who 
underwent a laparoscopic approach showed a significantly 
shorter length of stay (primary outcome), longer median 
operative time, and less severe complications (Clavien-
Dindo grade > 3 complications), lower Comprehensive 
Complication Index score and the number of patients with 
poor quality outcomes, as compared to those who underwent 
open surgery [28].
What should be the extent of lymphadenectomy 
in the surgical treatment of PC?
Pancreatectomy with standard lymphadenectomy including 
at least 15 lymph nodes should be the procedure of choice 
in PC. There is no evidence that extended lymphadenectomy 
results in a survival benefit in PC, and it increases periopera-
tive complications [29, 30] (quality of evidence: A; strength 
of recommendation: strong).
When and how is vascular resection performed?
Vascular involvement has traditionally been considered a 
formal contraindication for resection [5, 8]. Venous resec-
tion and reconstruction to achieve R0 resection is an optimal 
Table 1  Definition of resectability according to NCCN guidelines [8]
Resectability status Arterial Venous
Resectable No arterial tumor contact: celiac axis (CA), superior mes-
enteric artery (SMA), or common hepatic artery (CHA)
No tumor contact with the superior mesenteric vein (SMV) 
or portal vein (PV) or ≤ 180° contact without vein contour 
irregularity
Borderline resectable Pancreatic head/uncinate process:
Solid tumor with CHA without extension to the celiac axis 
or hepatic artery bifurcation allowing safe and complete 
resection and reconstruction
Solid tumor contact with the SMA ≤ 180°
Solid tumor contact with variant arterial anatomy (e.g., 
accessory right hepatic artery, replaced right hepatic 
artery, replaced CHA, and the origin of replaced or 
accessory artery) and the presence and degree of the 
tumor should be noted if present, as it may affect surgical 
planning
Pancreatic body/tail:
Solid tumor contact with the CA of ≤ 180°
Solid tumor contact with the CA of > 180° without involve-
ment of the aorta and with intact and uninvolved gas-
troduodenal artery (some members prefer these criteria to 
be in the unresectable category)
Solid tumor contact with the SMV or PV of > 180°, contact 
of ≤ 180° with contour irregularity of the vein or thrombo-
sis of the vein but with suitable vessels proximal and dis-
tal to the site of involvement allowing safe and complete 
resection and vein reconstruction
Solid tumor contact with the inferior vena cava (IVC)
Unresectable Distant metastases
Pancreatic head/uncinate process:
Solid tumor contact with SMA > 180°
Solid tumor contact with the CA > 180°
Solid tumor contact with the first jejunal SMA branch
Body and tail:
Solid tumor contact with the SMA or CA
Solid tumor contact with the CA and aorta
Pancreatic head/uncinate process:
Unreconstructible SMV/PV due to tumor involvement or 
occlusion (can be due to tumor or bland thrombus)
Contact with most proximal draining jejunal branch into 
SMV
Body and tail:
Unreconstructible SMV/PV due to tumor involvement or 
occlusion (can be due to the tumor or a bland thrombus)
1966 Clinical and Translational Oncology (2020) 22:1963–1975
1 3
procedure with similar overall survival and morbidity com-
pared to surgery without venous resection [31, 32]. How-
ever, arterial resection during pancreatoduodenectomy is 
associated with increased mortality and morbidity (bowel 
ischemia, hemorrhage, thrombosis) and is not recommended 
[33]. Progress in neoadjuvant therapies has allowed the 
downstaging of tumors with arterial invasion to borderline 
resectable or resectable disease, making surgical resection 
more achievable [34]. Despite these advancements, it is cur-
rently accepted that arterial reconstruction is only appropri-
ate in highly selected patients in high-volume centers with 
surgeons who are familiar with the advanced techniques 
required for reconstruction [35] (quality of evidence: B; 
strength of recommendation: strong).
When should a total pancreatectomy be considered 
in PC?
In patients with PC, a total pancreatectomy should be con-
sidered in patients with multifocal PC or locally advanced 
tumors who undergo pancreatectomy with arterial resection 
and reconstruction. It may be an alternative to pancreatic 
anastomosis in highly selected patients with a high-risk 
pancreas (soft texture and small pancreatic duct) and obese 
patients with pancreatic fat infiltration [36, 37] (quality of 
evidence: B; strength of recommendation: weak).
What is the role of staging laparoscopy for assessing 
resectability in PC?
Laparoscopy is useful in the discovery of small superficial 
liver and peritoneal metastases not visible by preopera-
tive MDCT. Staging laparoscopy can be recommended for 
patients with borderline resectable disease when neoadjuvant 
treatment is considered and in patients with an increased risk 
of disseminated disease (tumors in the body and tail of the 
pancreas, size > 3–4 cm, high CA 19.9 levels, presence of 
ascites or large regional lymph nodes), or highly sympto-
matic (back pain, severe weight loss) [8, 38, 39] (quality of 
evidence: B; strength of recommendation: strong).
Is there an indication for surgical resection 
of metastases in patients with PC?
Patients with PC and distant metastases are considered 
unresectable, and palliative chemotherapy is the standard 
of care [8]. However, highly selected patients with resectable 
solitary hepatic or pulmonary metastases may potentially 
benefit from surgical resection when an R0 resection can 
be achieved by pancreatectomy and metastasectomy, when 
metastases remain stable or decrease in size with neoad-
juvant chemotherapy and in patients without significant 
comorbidities and with good performance status [8, 40–42] 
(quality of evidence: C; strength of recommendation: weak).
What should be the recommended annual minimum 
volume of patients per center and surgeon to obtain 
optimal surgical results in PC surgery?
An experienced high-volume pancreatic center is recom-
mended for the surgical treatment of PC. Higher hospital 
volume is associated not only with reduced perioperative 
morbidity, mortality, length of hospital stay, and hospital 
costs but also with a higher chance of undergoing a radi-
cal resection, receiving adjuvant treatment, and longer 
survival [43–45]. Although consensus regarding the defini-
tion of high-volume centers and surgeons is needed, it is 
recommended that resections be performed at institutions 
that perform a large number (at least 15–20) of pancreatic 
resections annually [8]. Regarding the definition of high-
volume surgeons, studies vary in the number of pancrea-
ticoduodenectomies per year, ranging from 6 to > 20 pan-
creaticoduodenectomies/year [44] (quality of evidence: B; 
strength of recommendation: weak).
Systemic treatment
When is neoadjuvant treatment indicated?
Neoadjuvant treatment aims to increase overall survival by 
increasing the rate of R0 resection and early treatment of 
micrometastatic disease. For patients with resectable dis-
ease, neoadjuvant treatment cannot be recommended outside 
a clinical trial. Preoperative treatment for 3–4 months is the 
preferred approach in patients with borderline resectable 
disease [46, 47] (quality of evidence: B; strength of recom-
mendation: moderate).
Afterwards, the patient should be under continuous evalu-
ation by the multidisciplinary team. A lack of an objective 
radiological response should not be a criterion to rule out 
surgical resection. Patients with suspected disease progres-
sion by elevated CA 19.9 without radiological evidence of 
disease progression should be carefully evaluated, and PET 
scan and laparoscopy should be considered. Patients with 
documented metastatic progression are not candidates for 
surgery and should be managed as such [48].
What is the neoadjuvant treatment indicated 
in patients with borderline tumors?
The chemotherapy treatments used should be those associ-
ated with a higher response rate in patients with metastatic 
disease (gemcitabine [GEM]/nab-paclitaxel, FOLFIRINOX) 
[6, 49]. Radiotherapy alone is not recommended and should 
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be combined with either fluoropyrimidines or GEM [50, 
51]. Patients who receive chemoradiation should wait four 
to eight weeks before attempting surgical resection (quality 
of evidence: B; strength of recommendation: moderate).
Which neoadjuvant treatment is indicated 
in patients with unresectable tumors?
Whenever there are no data with regard to the most efficient 
regimen in this particular setting, current trends are to use 
either GEM/nab-paclitaxel or FOLFIRINOX based on the 
data available for patients with advanced disease [6, 52]. 
Chemotherapy is usually administered for 3 to 4 months fol-
lowed by assessment of tumor response. Responding patients 
or patients with stable disease can continue chemotherapy, 
have a surgical resection or be treated with chemoradiation 
[51] (quality of evidence: B; strength of recommendation: 
moderate).
When should adjuvant therapy be 
given after surgical resection of PC?
Even with R0 resection, the recurrence rate is very high in 
PC. Adjuvant treatment is recommended in patients who 
undergo an R0/R1 resection with a PT1-4/N0-1M0, with an 
ECOG performance status of 0–1 and proper nutritional sta-
tus. As a result, adjuvant treatment is required in all patients 
with resected adenocarcinoma of the pancreas. It is often 
recommended that adjuvant treatment be initiated within 
the next 12 weeks after surgery in patients who do not have 
any serious postsurgical complication, active infection or 
signs or symptoms of recurrent disease [17] (quality of evi-
dence: A; strength of recommendation: strong).
There is no consensus on adjuvant treatment in patients 
who have received neoadjuvant treatment. In general, adju-
vant treatment in this population is still considered investi-
gational. Generally, patients who have received neoadjuvant 
treatment should receive adjuvant treatment to complete a 
total of 6 months of treatment [53].
What is the appropriate adjuvant treatment 
for patients with PC who underwent an R0 or R1 
resection?
Currently, until the results of ongoing studies become avail-
able, the standard treatment is GEM in combination with 
capecitabine in the adjuvant setting in PC [54]. In patients 
not considered for combination treatment, the best option 
is single-agent GEM or the combination of 5-fluorouracil 
(5-FU) and folinic acid for a total of 6 months [55, 56] (qual-
ity of evidence: A; strength of recommendation: strong).
What are the first‑line treatment options 
for metastatic PC?
The management of patients with advanced PC is based on 
systemic chemotherapy. For patients who are able to receive 
chemotherapy without limitations, the current standard of 
care is either GEM/nab-paclitaxel or FOLFIRINOX [6, 7]. 
In the absence of randomized studies comparing these two 
regiments, neither one can be recommended. Patients with 
ECOG 2 can be treated with GEM alone [57] (quality of 
evidence: A; strength of recommendation: strong).
The response to treatment should be monitored every 
8–12 weeks by a CT scan. The tumor marker CA 19.9 should 
be measured before treatment and every 4–8 weeks after 
treatment. Tumor progression in patients with rising CA 
19.9 should be confirmed radiologically [17]. Patients who 
are not candidates for chemotherapy should receive pallia-
tive treatment.
What is the treatment in patients with metastatic PC 
who progress after first‑line chemotherapy?
Second-line treatment will be considered in selected patients 
with good performance status after progression to first-line 
treatment [58]. For patients who have been treated with 
a GEM-based regimen, the FOLFOX regimen demon-
strated an improvement in survival compared to 5-FU in 
the CONKO-003 study [59]. However, these results with 
the addition of oxaliplatin to 5-FU were not confirmed in 
the PANCREOX trial [60]. Recently, the NAPOLI-1 study 
showed that NALIRI (liposomal formulation of irinotecan) 
in combination with 5-FU was better than 5-FU alone, with 
this combination being the best way to treat these patients 
[61]. For patients who have received 5-FU-based chemo-
therapy, there are very few data to base second-line choices 
on. In general, either GEM alone or a GEM combination 
is recommended [62] (quality of evidence: A; strength of 
recommendation: strong).
Radiotherapy
When is radiotherapy recommended in neoadjuvant 
treatment?
Initial neoadjuvant therapy is recommended for patients with 
borderline resectable disease based on small retrospective 
studies and meta-analyses. In this setting, the specific con-
tribution of radiation therapy (RT) to neoadjuvant chemo-
therapy remains unclear. The goals of neoadjuvant RT are to 
decrease viable cells at the periphery of the tumor, thereby 
improving the chance of a negative margin [63, 64] (qual-
ity of evidence: B; strength of recommendation: moderate).
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Neoadjuvant RT is usually administered concomitantly 
with chemotherapy after 2 or 3 cycles of induction chemo-
therapy if the patient remains free of distant metastases. Ste-
reotactic body radiotherapy (SBRT) can be considered in the 
neoadjuvant setting instead of conventional fractionation RT 
[65], although no randomized trials comparing this approach 
with conventional RT have been completed.
When is adjuvant radiation therapy indicated?
Chemoradiation has been used for resectable PC in the adju-
vant setting based on its potential to decrease the likelihood 
of local recurrence and disease progression; however, the 
ESPAC-1 trial failed to show an advantage of the addition 
of postoperative radiation [66], with chemotherapy alone 
remaining the standard of care in the adjuvant setting.
In contrast, in the GERCOR phase II study, the rate of 
local recurrence was notably lower (11% vs 24%) for the 
group treated with chemoradiotherapy [67]. To definitively 
clarify the role of postoperative radiotherapy, the RTOG is 
conducting a trial with overall survival as the primary end-
point, which is estimated to be completed in 2020. In the 
meantime, some consideration of postoperative radiotherapy 
can be given to special cases of R1 disease (quality of evi-
dence: B; strength of recommendation: moderate).
What is the role of radiotherapy in the treatment 
of unresectable PC?
In patients with unresectable PC, most guidelines (NCCN, 
ASCO, ESMO) recommend an initial period of chemother-
apy followed by either more chemotherapy or chemoradio-
therapy [8, 68]. Chemoradiation is mainly used in selected 
patients who do not develop metastatic disease during initial 
chemotherapy [50, 51]. Chemoradiation can also be given as 
second-line therapy in patients with locally advanced unre-
sectable disease if chemoradiation was not previously given 
and if the primary site is the sole site of progression. Finally, 
radiation alone can be used as palliative treatment for pain 
refractory to narcotic therapy (quality of evidence:  B; 
strength of recommendation: moderate).
Chemoradiation can obtain higher loco-regional disease 
control in patients with unresectable PC compared with that 
of chemotherapy alone, although a benefit in overall survival 
has not been clearly demonstrated [69]. Chemoradiation can 
also increase the R0 resection rate in patients with unresect-
able disease who can finally be operated on [70].
What are the most appropriate radiation doses 
and techniques to treat PC?
Pancreatic tumors are usually surrounded by multiple sensi-
tive structures, such as the great vessels, the duodenum and 
the stomach. It is therefore important to use an advanced 
radiation technique capable of delivering a high dose of radi-
ation to the tumor while minimizing toxicity to neighboring 
tissues. 3-D conformal RT (3D-CRT), intensity-modulated 
RT (IMRT), and SBRT can result in improved tumor cover-
age with decreased dose to adjacent organs at risk [51, 65, 
71–73] (quality of evidence: B; strength of recommendation: 
strong).
For resectable/borderline/unresectable chemoradiation, 
45–54 Gy in 1.8–2 Gy fractions is usually used. Addition-
ally, 36 Gy in 2.4 fractions has been reported for preop-
erative chemoradiation [72]. SBRT uses hypofractiona-
tion, typically 3–7 fractions of 10–15 Gy. For adjuvant 
chemoradiation, the radiotherapy dose generally consists of 
45–46 Gy in 1.8–2 Gy fractions to the tumor bed, surgical 
anastomoses and adjacent lymph node basins, potentially 
followed by an additional 5–9 Gy to the tumor bed [73].
Palliative treatment
For patients with unresectable/metastatic PC, what 
is the preferred method for the management of bile 
duct obstruction?
Endoscopic retrograde stenting is superior to surgical or per-
cutaneous approaches because of a more favorable adverse 
event rate [74]. Self-expandable metal stents are superior 
to plastic stents in patients with a life expectancy of more 
than 3 months in terms of patency duration (approximately 
8–12 vs 2–4 months), less therapeutic failure, less need for 
reintervention, lower cholangitis incidence and better patient 
quality of life [74–76]. Patency rates between covered and 
uncovered metal stents are not significantly different [77].
Percutaneous and endoscopic ultrasound (EUS)-guided 
biliary drainage are alternative methods if endoscopic biliary 
stent placement is unsuccessful or technically not feasible 
[23] (quality of evidence: A; strength of recommendation: 
strong).
For patients with unresectable/metastatic 
PC, what are the recommended strategies 
for the management of gastric outlet obstruction?
Endoscopic duodenal stenting allows a quick resumption 
of oral intake, with a low complication rate and a short 
recovery period. However, the need for reintervention is 
higher after duodenal stenting compared with that of pallia-
tive surgery [78]. EUS-guided gastrojejunostomy has been 
developed as an effective and safe alternative to surgery [79] 
(quality of evidence: C; strength of recommendation: weak).
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For patients with unresectable/metastatic 
PC, what are the recommended strategies 
for the management of pain?
Optimal management of pain in PC should follow a multi-
disciplinary approach [80]. The main treatment options are 
chemotherapy, analgesics and interventional techniques. 
Chemotherapy may decrease pain by reducing tumor growth, 
local neural invasion and inflammation [81]. Current guide-
lines for analgesic therapy in PC follow the principles of 
the analgesic ladder provided by the World Health Organi-
zation [82]. EUS- or CT-guided celiac plexus neurolysis is 
the interventional technique of choice for pain in PC and 
should be evaluated mainly in patients with severe pain 
requiring a high dose of potent narcotics. It is associated 
with pain relief in 54–88% of cases, improved quality of 
life and decreased opioid consumption [83, 84] (quality of 
evidence: B; strength of recommendation: strong).
Palliative radiation therapy may also significantly allevi-
ate pain due to local invasion of pancreatic cancer. A short 
course of external RT with or without concomitant chemo-
therapy is associated with the resolution of cancer-related 
pain in 35–65% of patients [85].
Pathology
Is it necessary to analyze intraoperative frozen 
sections of resection margins during pancreatic 
resections?
The pancreatic neck transection margin has been shown to 
be an important prognostic factor in PC and can be extended 
if tumor involvement is identified on intraoperative frozen 
sections to achieve a negative margin [86]. The common 
bile/hepatic duct transection margin should also be evaluated 
[87] (quality of evidence: A; strength of recommendation: 
strong).
What is the best gross dissection protocol 
of the resection specimen of PC?
The use of a standardized pathology protocol based on axial 
slicing perpendicular to the long axis of the duodenum is 
recommended. The dissection technique results in 6–8 slices, 
allowing thorough examination of the tumor site and its rela-
tionship to the key anatomic structures (duodenum, common 
bile duct, peripancreatic soft tissue) and margins [88]. The 
examination of six distinct margins is recommended. The 
two transection margins are those of the pancreatic neck and 
the common bile duct. The four circumferential margins are 
the superior mesenteric vein margin, the superior mesenteric 
artery margin, the posterior margin, and the anterior surface 
of the pancreas [88, 89]. A careful sampling of the lymph 
nodes must be performed [88, 89] (quality of evidence: A; 
strength of recommendation: strong).
When is a resection considered R0?
As a result of the infiltrating and often discontinuous pat-
tern of PC growth, a minimum clearance of > 1 mm should 
be required to obtain a potentially curative resection [90]. 
R1 was defined when the distance of the tumor from the 
resection margin was ≤ 1 mm. The infiltration of the margin 
was further defined as “direct extension of the primary neo-
plasm” or lymph node metastasis or perineural/lymphatic/
vascular tumor propagation ≤ 1 mm of the margin [91] (qual-
ity of evidence: A; strength of recommendation: strong).
How many lymph nodes should be histologically 
examined to improve staging accuracy?
As in any other organs, the N-stage is one of the best prog-
nosticators in PC. Studies have shown that the best prognos-
tic value is achieved if 15 lymph nodes are examined, and 
patients with fewer lymph nodes evaluated following surgery 
may be understaged [90]. It should be noted that the total 
number of positive lymph nodes and the ratio of metastatic 
to examined lymph nodes (LNR) are powerful predictors of 
survival in patients with PC [90] (quality of evidence: A; 
strength of recommendation: strong).
What pathological parameters should be evaluated 
in the assessment of the resection specimen with PC 
and after neoadjuvant therapy?
The histopathological assessment of resected specimens 
should include the parameters listed in Table 2. After neoad-
juvant therapy, the College of American Pathologists (CAP) 
recommends a 4-tier scheme for tumor regression score for 
determining the treatment effect based on the amount of 
residual viable tumor cells [92, 93] (Table 3) (quality of 
evidence: A; strength of recommendation: strong).
What molecular‑pathological studies should be 
performed in PC? What prognostic information 
do these studies provide?
Whole-exome sequencing reaffirmed known mutations 
in KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, 
ARID1A and ATM [94]. More recent studies using next-
generation sequencing techniques with whole-genome or 
exome sequencing have identified additional genetic alter-
ations, including alterations in genes that play a central 
role in DNA repair. Germline and somatic mutations in 
the DNA damage repair genes BRCA2, BRCA1, PALPB2 
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and ATM were observed in 10% of samples, representing 
a class of patients for whom platinum-based chemotherapy 
and/or PARP inhibition may have therapeutic benefits [95].
One recently identified subtype within the genomic 
landscape of PC is the mismatch repair-deficient (MMR-
D) tumor, which is present in < 1% of all PC patients and 
is typically associated with a germline mutation in MMR 
genes. MMR-D PC has a tendency to be associated with 
intraductal mucinous papillary neoplasm (IPMN) and a 
more favorable natural history. MMR-D PC has also been 
reported to have a medullary histology associated with 
the wild-type KRAS gene [96] (quality of evidence: B; 
strength of recommendation: moderate).
What are the requirements of fine‑needle aspiration 
(FNA) and fine‑needle biopsy (FNB) for an adequate 
cytohistological evaluation of PC?
The diagnostic accuracy of EUS-FNA is reported to be 
over 90% in most studies when rapid on-site evaluation 
for cytopathology samples is employed. One or two passes 
usually allow the pathologist to evaluate the sample smears 
for diagnostic yield. Further passes may be made as needed 
to achieve diagnostic success [97] (quality of evidence: A; 
strength of recommendation: strong).
In theory, an FNB, or core-needle biopsy, contains a 
superior tissue sample with preserved cellular architecture 
compared to that from FNA. The randomized studies com-
paring FNA and core biopsy have produced different con-
clusions. Given the increased use of molecular studies on 
tissue samples required for gene-specific oncologic therapy, 
obtaining histologically sized specimens, rather than cytopa-
thology, will be of importance in the future [97] (quality of 
evidence: B; strength of recommendation: moderate).
Follow‑up
What is the recommended frequency of follow‑up/
surveillance after potentially curative treatment 
of PC?
MDCT is the primary imaging modality for monitoring fol-
lowing chemotherapy or surgery. Although MDCT scans 
may detect locally recurrent or metastatic disease, there 
is no evidence that regular follow-up after initial therapy 
with curative intent has any impact on the outcome [4, 17, 
98]. We propose to follow-up patients with PC after sur-
gical resection with measurement of tumor markers and 
a dynamic CT scan every 3–6 months for 2 years postop-
eratively and every 6–12 months subsequently, for at least 
5 years postoperatively (quality of evidence: C; strength of 
recommendation: moderate). In unresectable PC, imaging 
intervals can be increased to every 6 months once stability 
is comfortably established [69], and in metastatic patients 
outside a clinical trial, to assess first response, a CT scan 
should be offered at 2 or 3 months after the initiation of 
therapy [98].
Table 2  Pathological parameters evaluated in the assessment of the 
resection specimen with PC
*Requires assessment of peripancreatic tissue invasion and involve-
ment of the intrapancreatic common bile duct, duodenum and 
ampulla of Vater
-Type of specimen
-Maximum size of the tumor
-Histological type (WHO classification of exocrine pancreatic carci-
nomas) (Appendix A)
-Histological grading (Appendix B)
-Local invasion*
-Perineural, lymphatic and vascular vessel invasion
-Superior mesenteric vein or portal vein involvement
-Resection margins:
  +Surgical transection margins:
  •Pancreatic neck
  •Common bile duct
 + Circumferential resection margins:
  •Superior mesenteric vein margin
  •Superior mesenteric artery margin
  •Posterior margin
  •Anterior surface of the pancreas
- Lymph node involvement
  •Total number of nodes examined
  •Number of metastatic nodes
-UICC TNM staging  (8th edition)
-Completeness of excision (R category)
Table 3  The CAP tumor 
regression grading system
Grade Proportion of residual viable tumor
0 No viable cancer cells (complete histological response)
1 Single cells or rare small groups of cancer cells (nearly complete response)
2 Residual cancer with evident tumor regression, but more than single cells or rare 
small groups of cancer cells (partial response)
3 Extensive residual cancer with no evident tumor regression (poor or no response)
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Nutritional support, pancreatic exocrine 
insufficiency, and diabetes mellitus
How and when do we assess nutritional status 
in patients with PC before surgery? If nutritional 
support is needed, by what means should it be 
administered?
Because malnourished patients suffer increased postopera-
tive morbidity after duodenopancreatectomy, some nutrition 
assessment screening tools that track body mass index and 
the amount of weight loss are mandatory [99]. It is strongly 
recommended to start nutrition therapy early, as soon as a 
nutritional risk becomes apparent. Routine use of preop-
erative artificial nutrition is not warranted, but significantly 
malnourished patients should be optimized. A preoperative 
nutrition intervention plan includes dietary advice and oral 
nutritional supplements (ONS) if the dietary intake is less 
than 75% [99]. Parenteral nutrition should be used only if the 
enteral route is inaccessible [100] (quality of evidence: A; 
strength of recommendation: strong).
What is the optimal nutritional support 
after surgery? What recommendations 
regarding diet and intake of nutrients can be 
given to patients with PC at discharge?
The ERAS guidelines [100] recommend a “normal diet”, 
as soon as possible, in patients at low risk of pancreatic 
fistula (first postoperative day [POD] drain fluid amyl-
ase < 350  IU/L) [101]. Patients should increase intake 
according to tolerance over 3–4 days. There was some het-
erogeneity in the planned schedule for the initiation of clear 
fluids (from 0–3 POD) and solid food/regular diet (from 
POD 3–5). ONS should be considered if oral intake is less 
than 75% [102]. An enteral feeding tube vs a catheter jeju-
nostomy should be given only with specific indications. Par-
enteral nutrition should not be employed routinely [103]. 
After discharge, we recommended a normal diet, including 6 
to 8 meals or snacks each day [102] (quality of evidence: B; 
strength of recommendation: strong).
What is the recommended management 
for the treatment of diabetes mellitus 
and pancreatic exocrine insufficiency (PEI) 
before and after surgery for PC?
Type 3c diabetes occurs because of a variety of exocrine pan-
creatic diseases, including PC [104]. Metformin or insulin is 
used as a first-line therapy [105]. A high prevalence of PEI 
is observed in PC patients. Pancreatic enzyme replacement 
therapy (PERT) remains the mainstay of treatment. The ini-
tial dose is 75,000 Ph.U. of lipase/meal. Acid-suppressing 
therapy is frequently needed due to the reduced or abolished 
pancreatic bicarbonate secretion. Nutritional management 
by an experienced dietitian is essential [106] (quality of evi-
dence: B; strength of recommendation: strong).
What is the recommended nutritional support 
in patients with unresectable PC?
The nutritional status of patients with advanced cancer must 
be assessed since there is a clear benefit of nutritional sup-
plementation on survival time, performance status, and QoL 
[107]. It is important that vitamin D and PEI be treated as 
well as other concomitant symptoms that affect appetite and 
food intake, such as mechanical or functional gastrointestinal 
disorders, depression and fatigue [108]. Specific nutrients, 
such as N3-fatty acids, l-carnitine, antioxidants, branched-
chain amino acids and lactoferrin, can be administered to 
fight cachexia, but the overall results remain inconclusive 
[107, 108]. For patients with cancer who are nearing the 
end of life, nutrition is tailored to the patient’s symptomatic 
needs and is primarily intended to support comfort and QoL 
[109] (quality of evidence: B; strength of recommendation: 
strong).
What is the recommended management 
for the treatment of diabetes mellitus and PEI 
in patients with unresectable PC?
PEI is very frequent (> 90% when the tumor is located in 
the head of the pancreas), and it has been associated with 
higher mortality in patients with unresectable PC [110]. Pan-
creatic enzyme replacement therapy improves survival in 
these patients [111, 112]. The recommended starting dose 
is 75,000 Ph.U./meal. The addition of a PPI is frequently 
needed. The diet should not be low in fat to achieve a better 
effect [113]. The elastase-1 stool test has been shown to be a 
simple, noninvasive, low-cost technique with an acceptable 
correlation with secretory tests [113].
The presence of diabetes has been associated with higher 
mortality in patients with unresectable PC [114]. High-
dose glucocorticosteroids can induce or exacerbate diabe-
tes. Careful monitoring of plasma glucose levels 2 h after 
lunch is widely recommended. The limited literature on 
this topic recommends maintaining blood glucose levels to 
avoid hypoglycemia and reduce symptoms of hyperglycemia 
[115]. Insulin is considered the preferred agent because of its 
efficacy, flexibility, and safety [115] (quality of evidence: B; 
strength of recommendation: strong).
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